Skip to main content
Log in

Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost

  • Case Report
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

This paper describes a 61-year-old woman who presented with mixed connective tissue disease, which was complicated by the development of pulmonary arterial hypertension (PAH). Her condition worsened rapidly, with development of haemopthysis, tachypnoe and cardiac arrest. Doppler echocardiography showed a high systolic pulmonary arterial pressure (98 mmHg), confirmed by the right heart catheterization. Vasculopathy of the pulmonary artery vessels was detected following open lung biopsy. No pulmonary embolism was found. Because of suspicion of flare of her underlying disease, which leads to PAH, immunosuppressive treatment was started with high doses of corticosteroid and cyclophosphamide, in combination with the prostacyclin analogue, Iloprost, and low molecular weight heparin. The therapy resulted in slow recovery over 6 weeks, with control echocardiography showing normalization of the high pulmonary pressure, and the patient being capable of returning to everyday activities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Abbreviations

PAP:

Pulmonary arterial pressure

RA:

Right atrial

TR:

Tricuspid regurgitation

vWFAg (<120%):

von Willebrand Factor antigen

AECA (<35 U/ml):

Anti-endothelial cell antibodies

aU1RNP (<5 U/ml):

Anti-U1RNP antibody

TM (<3.9 ng/ml):

Thrombomodulin

References

  1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR (1972) Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159

    Article  PubMed  Google Scholar 

  2. Alarcon-Segovia DA, Villarreal M (1987) Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and anti-nuclear antibodies. Excerpta Medica, Amsterdam, pp 33–40

    Google Scholar 

  3. Smolen JS, Steiner G (1998) Mixed connective tissue disease: to be or not to be?. Arthritis Rheum 41:768–777

    Article  PubMed  Google Scholar 

  4. Hoffman RW, Greidinger EL (2000) Mixed connective tissue disease. Curr Opin Rheumatol 12:386–390

    Article  PubMed  Google Scholar 

  5. Sharp GC (1974) Mixed connective tissue disease. Bull Rheum Dis 25:828–831

    PubMed  Google Scholar 

  6. Sullivan WD, Hurst DJ, Harmon CE, Esther JH (1984) A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine 63:92–107

    PubMed  Google Scholar 

  7. Eulderink F, Cats A (1981) Fatal pulmonary hypertension in mixed connective tissue disease. Z Rheumatol 40:25–29

    PubMed  Google Scholar 

  8. Suzuki M, Hamada M, Sekiya M, Shigematsu Y, Go S, Hiwada K (1992) Fatal pulmonary hypertension in a patient with mixed connective tissue disease: report of an autopsy case. Intern Med 31:74–77

    PubMed  Google Scholar 

  9. Ueda N, Mimura K, Sugiyama T, Kado T (1984) Mixed connective tissue disease with fatal pulmonary hypertension and a review of literature. Virchows Arch (Pathol Anat) 404:335–340

    Article  Google Scholar 

  10. Hosoda T (1987) Review of pathology of mixed connective tissue disease. In: Kasukawa R, Sharp GC (eds) Mixed connective tissue disease and anti-nuclear antibodies. Excerpta Medica, Amsterdam, pp 281–290

    Google Scholar 

  11. Rosenberg AM, Petty RE, Cumming GR, Koechler B (1976) Pulmonary hypertension in a child with mixed connective tissue disease. J Rheumatol 6:700–704

    Google Scholar 

  12. Alpert MA, Goldberg SH, Singsen BH, Durham JB, Sharp GC, Ahmad M et al (1983) Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 68:1182–1193

    PubMed  Google Scholar 

  13. Burdt MA, Hoffman RW, Deutscher SL, Wang GS (1999) Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 42:899–909

    PubMed  Google Scholar 

  14. Jones MB, Osterholm RK, Wilson RB, Martin FH, Commers JS, Bachmayer JD (1978) Fatal pulmonary hypertension and resolving immune-complex glomerulonephritis in mixed connective tissue disease. Am J Med 65:855–863

    Article  PubMed  Google Scholar 

  15. Wiener-Kronish JP, Solinger AM, Warnock ML, Churg A, Ordonez N, Golden JA (1981) Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 124:499–503

    PubMed  Google Scholar 

  16. Manthorphe R, Elling H, van der Meulen JT, Freiesleben Sorensen S (1980) Two fatal cases of mixed connective tissue disease. Scand J Rheumatol 9:7–10

    PubMed  Google Scholar 

  17. Prakash UBS (1988) Pulmonary manifestations in mixed connective tissue disease. Seminars Resp Med 9:318–324

    Google Scholar 

  18. Prakash UBS (1998) Respiratory complications in mixed connective tissue disease. Clin Chest Med 19:733–746

    PubMed  Google Scholar 

  19. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC (2003) Age and risk of pulmonary arterial hypertension in scleroderma. Chest 124:2098–2104

    Article  PubMed  Google Scholar 

  20. Mukerjee D, St. George D, Knight C, Davar J, Wells AU, Du Bois RM, Black CM, Coghlan JG (2004) Echocardiography and pulmonary function as creeening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 43:461–466

    Article  PubMed  Google Scholar 

  21. Ozawa T, Ninomiya Y, Honma T, Kikuchi M, Sato T, Nakano M, Arakawa M (1995) Increased serum angiotensin I-Converting enzyme activity in patients with mixed connective tissue disease and pulmonary hypertension. Scand J Rheumatol 24:38–43

    PubMed  Google Scholar 

  22. Manganelli P, Salaffi F, Carotti M, Delsante G, Mozzani F (1999) Pulmonary hypertension in rheumatic diseases. Minerva Med 90:59–72

    PubMed  Google Scholar 

  23. Miyata M, Suzuki K, Sakuma F, Watanabe H, Kaise S, Nishimaki T, Kasukawa R (1993) Anticardiolipin antibodies are associated with pulmonary hypertension in patients with mixed connective tissue disease or systemic lupus erythematosus. Int Arch Allergy Immunol 100:351–354

    PubMed  Google Scholar 

  24. Sasaki N, Kurose A, Inoue H, Sawai T (2002) A possible role of anti-endothelial cell antibody in the sera of MCTD patients on pulmonary vascular damage relating to pulmonary hypertension. Ryumachi 42:885–894

    PubMed  Google Scholar 

  25. Nishimaki T, Aotsuka S, Kondo H (1999) Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 26:2357–2362

    PubMed  Google Scholar 

  26. Klings ES, Hill NS, Ieong MH, Sims RW, Korn JH, Farber HW (1999) Systemic sclerosis-associated pulmonary hypertension. Arthritis Rheum 42:2638–2645

    Article  PubMed  Google Scholar 

  27. Nicod LP (2003) Pulmonary hypertension. Swiss Med Wkly 133:103–110

    PubMed  Google Scholar 

  28. Magliano M, Isenberg DA, Hillson J (2002) Pulmonary hypertension in autoimmune rheumatic diseases. Arthritis Rheum 46:1997–2009

    Article  PubMed  Google Scholar 

  29. Hoeper MM, Scharze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J (2000) Long-term treatment of primary pulmonary hypertension with aerosolised iloprost, a prostacyclin analogue. N Engl J Med 342:1866–1870

    Article  PubMed  Google Scholar 

  30. Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of Iloprost: in vitro downregulation of endothelial cell adhesion molecules. Prostaglandins 65:73–83

    PubMed  Google Scholar 

  31. Bettoni L, Geri A, Airo P, Danieli E, Cavazzana I, Antonioli C, Chiesa L, Franceschini F, Grottolo A, Zambruni A, Radaeli E, Cattaneo R (2002) Systemic sclerosis therapy with Iloprost: A prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 21:244–250

    PubMed  Google Scholar 

  32. Chouat A, Weitzenblum E, Higenbottam T (1996) The role of thrombosis in severe pulmonary hypertension. Eur Respir J 9:356–363

    Article  PubMed  Google Scholar 

  33. Mehta NJ, Khan IA, Mehta RN et al (2000) HIV related pulmonary hypertension. Chest 118:1133–1141

    Article  PubMed  Google Scholar 

  34. Rich S, Kaufman E, Levy PS (1992) The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76–81

    PubMed  Google Scholar 

  35. Frank H, Mlczoch J, Huber K et al (1997) The effect of anticoagulant therapy in primary and anorectic drug induced pulmonary hypertension. Chest 112:714–721

    PubMed  Google Scholar 

  36. Kotajuma L, Aotsuka S, Sato T (1997) Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases. Clin Exp Rheumatol 15:59–65

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edit Bodolay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Végh, J., Soós, G., Csipõ, I. et al. Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatol Int 26, 264–269 (2006). https://doi.org/10.1007/s00296-005-0616-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-005-0616-8

Keywords

Navigation